Structure–Activity Relationships and Mechanism of Action of Eph–ephrin Antagonists: Interaction of Cholanic Acid with the EphA2 Receptor

The Eph–ephrin system, including the EphA2 receptor and the ephrinA1 ligand, plays a critical role in tumor and vascular functions during carcinogenesis. We previously identified (3α,5β)‐3‐hydroxycholan‐24‐oic acid (lithocholic acid) as an Eph–ephrin antagonist that is able to inhibit EphA2 receptor activation; it is therefore potentially useful as a novel EphA2 receptor‐targeting agent. Herein we explore the structure–activity relationships of a focused set of lithocholic acid derivatives based on molecular modeling investigations and displacement binding assays. Our exploration shows that while the 3‐α‐hydroxy group of lithocholic acid has a negligible role in recognition of the EphA2 receptor, its carboxylate group is critical for disrupting the binding of ephrinA1 to EphA2. As a result of our investigation, we identified (5β)‐cholan‐24‐oic acid (cholanic acid) as a novel compound that competitively inhibits the EphA2–ephrinA1 interaction with higher potency than lithocholic acid. Surface plasmon resonance analysis indicates that cholanic acid binds specifically and reversibly to the ligand binding domain of EphA2, with a steady‐state dissociation constant (KD) in the low micromolar range. Furthermore, cholanic acid blocks the phosphorylation of EphA2 as well as cell retraction and rounding in PC3 prostate cancer cells, two effects that depend on EphA2 activation by the ephrinA1 ligand. These findings suggest that cholanic acid can be used as a template structure for the design of effective EphA2 antagonists, and may have potential impact in the elucidation of the role played by this receptor in pathological conditions.

[1]  Elena B Pasquale,et al.  Cancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms. , 2012, Biochemistry.

[2]  R. Noberini,et al.  Targeting Eph receptors with peptides and small molecules: progress and challenges. , 2012, Seminars in cell & developmental biology.

[3]  J. Himanen.  Ectodomain structures of Eph receptors. , 2012, Seminars in cell & developmental biology.

[4]  L. Flammini,et al.  Polyphenol rich botanicals used as food supplements interfere with EphA2-ephrinA1 system. , 2011, Pharmacological Research.

[5]  Jacob D. Durrant,et al.  Molecular dynamics simulations and drug discovery , 2011, BMC Biology.

[6]  N. Cosford,et al.  A Disalicylic Acid‐Furanyl Derivative Inhibits Ephrin Binding to a Subset of Eph Receptors , 2011, Chemical biology & drug design.

[7]  D. Cross,et al.  Inhibitors of the tyrosine kinase EphB4. Part 4: Discovery and optimization of a benzylic alcohol series. , 2011, Bioorganic & medicinal chemistry letters.

[8]  M. Incerti,et al.  Lithocholic Acid Is an Eph-ephrin Ligand Interfering with Eph-kinase Activation , 2011, PloS one.

[9]  S. Mittal,et al.  Emerging strategies for EphA2 receptor targeting for cancer therapeutics , 2011, Expert opinion on therapeutic targets.

[10]  Amedeo Caflisch,et al.  High‐Throughput Virtual Screening Using Quantum Mechanical Probes: Discovery of Selective Kinase Inhibitors , 2010, ChemMedChem.

[11]  Jens Pietzsch,et al.  Eph Receptors and Ephrin Ligands: Important Players in Angiogenesis and Tumor Angiogenesis , 2010, Journal of oncology.

[12]  Elena B. Pasquale,et al.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond , 2010, Nature Reviews Cancer.

[13]  A. Ardizzoni,et al.  Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion. , 2010, Journal of medicinal chemistry.

[14]  Daniele Piomelli,et al.  Discovery of potent and reversible monoacylglycerol lipase inhibitors. , 2009, Chemistry & biology.

[15]  Jimmy Lin,et al.  Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4 , 2009, Nature Genetics.

[16]  A. Caflisch,et al.  Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). , 2009, Journal of medicinal chemistry.

[17]  M. Buck,et al.  Ligand recognition by A‐class Eph receptors: crystal structures of the EphA2 ligand‐binding domain and the EphA2/ephrin‐A1 complex , 2009, EMBO reports.

[18]  H. Miao,et al.  Eph/ephrin signaling in epithelial development and homeostasis. , 2009, The international journal of biochemistry & cell biology.

[19]  W. Debinski,et al.  The EphA2 Receptor and EphrinA1 Ligand in Solid Tumors: Function and Therapeutic Targeting , 2008, Molecular Cancer Research.

[20]  G. Roth,et al.  Small Molecules Can Selectively Inhibit Ephrin Binding to the EphA4 and EphA2 Receptors* , 2008, Journal of Biological Chemistry.

[21]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[22]  T. Pawson,et al.  Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer , 2008, British Journal of Cancer.

[23]  G. Descamps,et al.  New lithocholic and chenodeoxycholic piperazinylcarboxamides with antiproliferative and pro-apoptotic effects on human cancer cell lines. , 2008, Bioorganic & medicinal chemistry.

[24]  Johan Auwerx,et al.  Targeting bile-acid signalling for metabolic diseases , 2008, Nature Reviews Drug Discovery.

[25]  Elena B Pasquale,et al.  Eph-Ephrin Bidirectional Signaling in Physiology and Disease , 2008, Cell.

[26]  Anthony M Giannetti,et al.  Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors. , 2008, Journal of medicinal chemistry.

[27]  S. Brenner,et al.  Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. , 2007, Cancer research.

[28]  E. Kolehmainen,et al.  Novel lithocholaphanes: Syntheses, NMR, MS, and molecular modeling studies , 2007 .

[29]  D. Mangelsdorf,et al.  Synthesis, characterization, and receptor interaction profiles of enantiomeric bile acids. , 2007, Journal of medicinal chemistry.

[30]  D. Sretavan,et al.  Eph/ephrin signaling as a potential therapeutic target after central nervous system injury. , 2007, Current pharmaceutical design.

[31]  A. Pini,et al.  Characterization of the branched antimicrobial peptide M6 by analyzing its mechanism of action and in vivo toxicity , 2007, Journal of peptide science : an official publication of the European Peptide Society.

[32]  Brian K Shoichet,et al.  Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. , 2006, Journal of medicinal chemistry.

[33]  E. Pasquale.  Developmental cell biology: Eph receptor signalling casts a wide net on cell behaviour , 2005, Nature Reviews Molecular Cell Biology.

[34]  D. M. Olive,et al.  Quantitative methods for the analysis of protein phosphorylation in drug development , 2004, Expert review of proteomics.

[35]  Pietro Cozzini,et al.  Getting it right: modeling of pH, solvent and "nearly" everything else in virtual screening of biological targets. , 2004, Journal of molecular graphics & modelling.

[36]  T. Willson,et al.  6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. , 2002, Journal of medicinal chemistry.

[37]  K. Kullander,et al.  Mechanisms and functions of eph and ephrin signalling , 2002, Nature Reviews Molecular Cell Biology.

[38]  P. Hünenberger,et al.  A fast SHAKE algorithm to solve distance constraint equations for small molecules in molecular dynamics simulations , 2001, J. Comput. Chem..

[39]  R. Phadke,et al.  A novel steroidal spin label for membrane structure studies: synthesis and applications , 1999, Steroids.

[40]  G. Yancopoulos,et al.  Ephrins and their receptors: a repulsive topic? , 1997, Cell and Tissue Research.

[41]  H. Schild,et al.  SOME QUANTITATIVE USES OF DRUG ANTAGONISTS , 1997, British journal of pharmacology and chemotherapy.

[42]  W. L. Jorgensen,et al.  Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .

[43]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[44]  Mark E. Tuckerman,et al.  Reversible multiple time scale molecular dynamics , 1992 .

[45]  L. Steinrauf,et al.  Synthesis and evaluation of sulfur-containing steroids against methylmercuric chloride toxicity. , 1978, Journal of pharmaceutical sciences.

[46]  J. Venhorst,et al.  Target-drug interactions: first principles and their application to drug discovery. , 2012, Drug discovery today.

[47]  G. Siegal,et al.  Fragment based lead discovery of small molecule inhibitors for the EPHA4 receptor tyrosine kinase. , 2012, European journal of medicinal chemistry.

[48]  M. Mor,et al.  Application of computational methods to the design of fatty acid amide hydrolase (FAAH) inhibitors based on a carbamic template structure. , 2011, Advances in protein chemistry and structural biology.

[49]  Rüdiger Klein,et al.  Bidirectional modulation of synaptic functions by Eph/ephrin signaling , 2009, Nature Neuroscience.

[50]  A. U. Siddiqui,et al.  Synthesis of C-24 β-lactams of bile acids , 1993 .

[51]  T. Huynh,et al.  Preparation and characterization of 3-monohydroxylated bile acids of different side chain length and configuration at C-3. Novel approach to the synthesis of 24-norlithocholic acid. , 1986, Journal of lipid research.

[52]  T. Fujioka,et al.  PREPARATION AND CHROMATOGRAPHY OF THE HYDROXAMIC ACIDS OF SOME BILE ACIDS , 1958 .